Nanexa AB

Equities

NANEXA

SE0007074166

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Stockholm Other stock markets 11:21:44 2024-04-29 am EDT			5-day change	1st Jan Change
0.62 ^SEK	+2.31%		-3.12%	-49.59%

Apr. 16	Nanexa AB Announces Approval of Clinical Trial Application for NEX-22 Study Delayed	CI
Mar. 08	Transcript : Nanexa AB - Special Call

Nanexa AB Reports Earnings Results for the First Quarter Ended March 31, 2023

May 04, 2023 at 02:00 am EDT

Nanexa AB (publ) reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported sales was SEK 13.47 million compared to SEK 5.23 million a year ago. Revenue was SEK 14.27 million compared to SEK 5.32 million a year ago.

Net loss was SEK 8.6 million compared to SEK 12.37 million a year ago. Basic loss per share from continuing operations was SEK 0.14 compared to SEK 0.24 a year ago.

Latest news about Nanexa AB

Nanexa AB Announces Approval of Clinical Trial Application for NEX-22 Study Delayed	Apr. 16	CI
Transcript : Nanexa AB - Special Call	Mar. 07
Nanexa AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 21	CI
Nanexa AB Announces Clinical Trial Application for NEX-22 Phase I Study Assess by EMA	Dec. 20	CI
Nanexa Signs Feasibility Study Contract for PharmaShell; Shares Jump	Nov. 29	MT
Nanexa AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 20	CI
Nanexa AB Completes Clinical Phase I Study with NEX-20	23-10-05	CI
Nanexa to Raise SEK121 Million via Rights Issue; Shares Drop 5%	23-09-22	MT
Nanexa Gets India Patent for PharmaShell Technology	23-08-30	MT
Nanexa AB Receives Patent in India	23-08-30	CI
Nanexa AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-23	CI
Nanexa AB Confirms Continued Positive Results from A New Preclinical Study of Nex-22	23-08-22	CI
Nanexa AB Obtains Pharmacokinetic Data from the NEX-20 Phase 1 Study Confirming Controlled Release of Lenalidomide	23-08-22	CI
Nanexa AB Approves Election of Jakob Dynnes Hansen as Member of the Board	23-06-09	CI
Nanexa Completes Recruitment for Phase 1 Myeloma Cancer Drug Study	23-06-09	MT
Nanexa AB Completes Planned Recruitment to the Phase 1 Study of NEX-20	23-06-09	CI
Nanexa AB Signs Contract with Leading International Diabetes Cro for Phase I Study with Nex-22	23-06-01	CI
Nanexa AB Announces Urban Paulsson and Bengt Gustavsson Declines Re-Election	23-05-10	CI
Nanexa AB Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-04	CI
Nanexa AB Announces Positive Outcome in the First Preclinical Study with NEX-22	23-03-23	CI
Nanexa AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022	23-02-16	CI
Nanexa AB announced that it has received SEK 17.2 million in funding from Novo Nordisk A/S	22-12-20	CI
Nanexa Starts the Phase 1 Study of NEX-20 According to Plan	22-12-06	CI
Nanexa, VitriVax Settle Patent Infringement Case Over Drug Delivery System	22-11-16	MT
Nanexa Obtains Swedish Approval to Start Clinical Trial for Myeloma Cancer Medication	22-11-14	MT

Chart Nanexa AB

Duration

Period

More charts

Company Profile

Nanexa AB is a Sweden-based company engaged in the drug delivery systems industry. The Company specializes in the nanotechnology and research and development in life science. Its products portfolio is comprised of PharmaShell, a drug delivery system that allows for targeting and dosing of drugs; antifungal coating, a system that protects medical products from the in-growth of fungi; and low-friction coating for peripheral venous catheters.

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-05-02 - Q1 2024 Earnings Release

More about the company